Quantumup
Baird reiterated $LYEL Outperform-$49 and said--Incrementally positive on external program update.
[ $GILD ACLX IOVA LEGN NVS ALLO AUTL]
Last Thursday, Kite/Gilead announced that the FDA placed a partial clinical hold on trials evaluating its autologous CD19/CD20 CAR-T therapy KITE-753 due to higher instances of Gr.3/4 ICANS.
While Lyell's ronde-cel is also a dual CD19/CD20 CAR-T, we believe ronde-cel's differentiated design and prophylactic steroids should help insulate the program from these safety risks.
Looking ahead, we await interim data from the pivotal PiNACLE study evaluating ronde-cel in 3L+ LBCL (likely at ASH, abstracts release November 4 at 9 a.m. ET), with PFS being the focus.
3

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault18.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault13.jpg)